Lisanti Capital Growth LLC Sells 65,980 Shares of SiBone $SIBN

Lisanti Capital Growth LLC reduced its position in shares of SiBone (NASDAQ:SIBN) by 39.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,545 shares of the company’s stock after selling 65,980 shares during the period. Lisanti Capital Growth LLC owned approximately 0.24% of SiBone worth $1,930,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. American Century Companies Inc. boosted its stake in SiBone by 11.1% in the first quarter. American Century Companies Inc. now owns 2,642,322 shares of the company’s stock valued at $37,072,000 after buying an additional 264,254 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of SiBone by 1.5% during the first quarter. Vanguard Group Inc. now owns 2,444,159 shares of the company’s stock valued at $34,292,000 after purchasing an additional 35,349 shares in the last quarter. First Light Asset Management LLC grew its position in SiBone by 41.8% in the 1st quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company’s stock worth $22,622,000 after purchasing an additional 475,426 shares in the last quarter. Nuveen LLC bought a new position in shares of SiBone during the 1st quarter worth approximately $18,605,000. Finally, Victory Capital Management Inc. boosted its stake in shares of SiBone by 55.0% in the 1st quarter. Victory Capital Management Inc. now owns 631,568 shares of the company’s stock worth $8,861,000 after buying an additional 224,190 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.

Insider Buying and Selling

In related news, CFO Anshul Maheshwari sold 3,461 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $15.57, for a total value of $53,887.77. Following the completion of the transaction, the chief financial officer owned 214,445 shares of the company’s stock, valued at approximately $3,338,908.65. The trade was a 1.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Anthony J. Recupero sold 3,833 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $15.62, for a total transaction of $59,871.46. Following the sale, the insider directly owned 275,288 shares in the company, valued at $4,299,998.56. This represents a 1.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 32,009 shares of company stock worth $485,884. 4.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on SIBN. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the stock an “overweight” rating in a report on Monday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a report on Wednesday, October 8th. Truist Financial dropped their target price on shares of SiBone from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. Finally, Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

SiBone Stock Up 3.8%

Shares of NASDAQ SIBN opened at $15.77 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.38 and a quick ratio of 7.00. The firm’s 50-day moving average is $15.23 and its two-hundred day moving average is $16.53. SiBone has a 12-month low of $11.70 and a 12-month high of $20.05. The company has a market capitalization of $680.32 million, a PE ratio of -28.16 and a beta of 0.81.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.